PATENT CLAIM ANALYSIS

Application Number: 16118760
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-03
Patent Classification: ["546", "119000"]

Abstract:
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Claim (Index 42):
The method of  claim 41 , wherein the therapeutic agent is a reverse transcriptase inhibitor, and is at least one of Zidovudine, Didanosine, Zalcitabine, ddA, Stavudine, Lamivudine, Abacavir, Emtricitabine, Entecavir, Apricitabine, Atevirapine, ribavirin, acyclovir, famciclovir, valacyclovir, ganciclovir, valganciclovir, Tenofovir, Adefovir, PMPA, cidofovir, Efavirenz, Nevirapine, Delavirdine, and Etravirine.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 96.0
- Lexical Diversity: 1.42308
- Patent Class: 546.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14984325', '15843598', '14984293', '15347468', '14984654']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8708580457598419
- 35 USC 102 Novelty (BERT): 0.6735980817550964
- Combined Prediction Score: 0.8511320493593675
- Mean Citation Score: 697.37725
- Max Citation Score: 724.7858
- Similarity Product: 660.896173238635

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test